SIGLEC1 and colorectal carcinoma: In contrast, the percentages of circulating CD14+CD169+MAC387+ monocytes in total circulating CD14+CD169+ monocytes in the CRC patients were lower than that in HC (76.31% vs. 80.15%, P = 0.0041, Fig 1F).